| Literature DB >> 33459422 |
Marina Kolesnichenko1, Nadine Mikuda1, Uta E Höpken2, Eva Kärgel1, Bora Uyar3, Ahmet Bugra Tufan1, Maja Milanovic4, Wei Sun5, Inge Krahn1, Kolja Schleich4, Linda von Hoff1, Michael Hinz1, Michael Willenbrock1, Sabine Jungmann1, Altuna Akalin3, Soyoung Lee4, Ruth Schmidt-Ullrich1, Clemens A Schmitt4, Claus Scheidereit1.
Abstract
The IκB kinase (IKK)-NF-κB pathway is activated as part of the DNA damage response and controls both inflammation and resistance to apoptosis. How these distinct functions are achieved remained unknown. We demonstrate here that DNA double-strand breaks elicit two subsequent phases of NF-κB activation in vivo and in vitro, which are mechanistically and functionally distinct. RNA-sequencing reveals that the first-phase controls anti-apoptotic gene expression, while the second drives expression of senescence-associated secretory phenotype (SASP) genes. The rapidly activated first phase is driven by the ATM-PARP1-TRAF6-IKK cascade, which triggers proteasomal destruction of inhibitory IκBα, and is terminated through IκBα re-expression from the NFKBIA gene. The second phase, which is activated days later in senescent cells, is on the other hand independent of IKK and the proteasome. An altered phosphorylation status of NF-κB family member p65/RelA, in part mediated by GSK3β, results in transcriptional silencing of NFKBIA and IKK-independent, constitutive activation of NF-κB in senescence. Collectively, our study reveals a novel physiological mechanism of NF-κB activation with important implications for genotoxic cancer treatment.Entities:
Keywords: DNA damage response; IκBα; NF-κB; SASP; senescence
Year: 2021 PMID: 33459422 PMCID: PMC7957429 DOI: 10.15252/embj.2019104296
Source DB: PubMed Journal: EMBO J ISSN: 0261-4189 Impact factor: 11.598